Welcome to LookChem.com Sign In|Join Free

CAS

  • or

16867-04-2

Post Buying Request

16867-04-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16867-04-2 Usage

Chemical Properties

khaki to grey or brown crystalline powder

Uses

2,3-Dihydroxypyridine(DHP) was used in the synthesis of DHP loaded amberlite XAD-2 via azo coupler. It was used in the synthesis of new macromolecular chelators by loading DHP on cellulose via linkers -NH-CH2-CH2-NH-SO2-C6H4-N=N- and -SO2-C6H4-N=N.

Definition

ChEBI: A dihydroxypyridine in which the two hydroxy groups are located at positions 2 and 3.

Check Digit Verification of cas no

The CAS Registry Mumber 16867-04-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,8,6 and 7 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 16867-04:
(7*1)+(6*6)+(5*8)+(4*6)+(3*7)+(2*0)+(1*4)=132
132 % 10 = 2
So 16867-04-2 is a valid CAS Registry Number.
InChI:InChI=1/C5H5NO2/c7-4-2-1-3-6-5(4)8/h1-3,7H,(H,6,8)

16867-04-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (L07104)  2,3-Dihydroxypyridine, 98%   

  • 16867-04-2

  • 25g

  • 725.0CNY

  • Detail
  • Alfa Aesar

  • (L07104)  2,3-Dihydroxypyridine, 98%   

  • 16867-04-2

  • 100g

  • 2792.0CNY

  • Detail
  • Aldrich

  • (122505)  2,3-Dihydroxypyridine  95%

  • 16867-04-2

  • 122505-25G

  • 1,490.58CNY

  • Detail
  • Aldrich

  • (122505)  2,3-Dihydroxypyridine  95%

  • 16867-04-2

  • 122505-100G

  • 4,967.82CNY

  • Detail

16867-04-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,3-Dihydroxypyridine

1.2 Other means of identification

Product number -
Other names 2(1H)-Pyridinone, 3-hydroxy-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16867-04-2 SDS

16867-04-2Related news

Influence of mineral supplementation on 2,3-Dihydroxypyridine (cas 16867-04-2) toxicity in Angora goats07/27/2019

To study the effect of mineral supplementation on 2,3-DHP toxicity, 16 mature Angora wethers were randomly allocated to four treatment groups (M, DM, D and C). Two hours after the morning feeding; group M received a mineral mixture of 2 g of Fe2(SO4)3 · 7H20, 2 g of MgSO4 · 7H20 and 2 g of ZnS...detailed

Ionization effects on the sensitized photooxidation of 2,3-Dihydroxypyridine (cas 16867-04-2) and 2,4-dihydroxypyridine: a kinetic study07/23/2019

The kinetics of the Rose Bengal (RB)-sensitized photooxidation of 2,3-dihydroxypyridine (2,3-DHP) and 2,4-dihydroxypyridine (2,4-DHP), two compounds profusely employed in multiple fields such as pesticides design, pharmacology, and clinical therapeutics have been studied in water at pH 5, 11 and...detailed

16867-04-2Relevant articles and documents

-

Moehrle,Weber

, p. 3779,3783 (1970)

-

DERMATOLOGICAL COMPOSITIONS AND METHODS

-

, (2008/06/13)

Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.

Treatment of diseases mediated by the nitric oxide/cGMP/protein kinase G pathway

-

, (2008/06/13)

Disclosed are methods and compositions for stimulating cellular nitric oxide (NO) synthesis, cyclic guanosine monophosphate levels (cGMP), and protein kinase G (PKG) activity for purposes of treating diseases mediated by deficiencies in the NO/cGMP/PKG signal transduction pathway, by administration of various compounds including alcohols, diols and/or triols and their analogues.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16867-04-2